Revised forecast
Fiscal year ending March 2027 · Full yearPrevious forecast published 15 May 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
For CAP-1002, the PDUFA date was extended from 22 August 2026 to 22 November 2026 due to the FDA's continued review. In addition, arbitration proceedings are continuing even if approval is granted, leaving the launch timing undecided.
| Item | Details |
|---|---|
| Net Sales | ¥200,000 millions → ¥191,000 millions（-4.5%） |
| Operating profit | ¥38,000 millions → ¥33,000 millions（-13.2%） |
| Profit attributable to owners of the parent | ¥30,300 millions → ¥27,000 millions（-10.9%） |
| Net income per share | ¥449.55 / sen → ¥400.46 / sen |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Full year |
| Publication date of previous forecast | 15 May 2026 |
| Previous-period results | Revenue: ¥170,771 million. Operating profit, profit before tax and profit for the year attributable to owners of the parent: not disclosed. |
| Reason for the revision | For CAP-1002, the PDUFA date was extended from 22 August 2026 to 22 November 2026 due to the FDA's continued review. In addition, arbitration proceedings are continuing even if approval is granted, leaving the launch timing undecided. |
| Dividend forecast revision | No revision |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.For the Duchenne muscular dystrophy treatment CAP-1002, the PDUFA date was extended from 22 August 2026 to 22 November due to the FDA's continued review. In addition, arbitration proceedings are continuing even if approval is granted, leaving the launch timing undecided.